This review concluded that non-vitamin-K-antagonist oral anticoagulants seem to be associated with significant reductions in the rates of stroke or systemic embolism, haemorrhagic stroke, and major bleeding when compared with warfarin in patients with previous stroke or transient ischaemic attack. Given a number of limitations with the review, the conclusions should be treated with caution.
Study selection
Phase III randomised controlled trials (RCTs) that compared a recently developed non-VKA oral anticoagulant with a VKA such as warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack were eligible for inclusion.
The non-VKAs evaluated in the included studies were rivaroxaban, dabigatran, and apixaban; all used warfarin as the comparator. Those who received warfarin spent between 57% to 65% of time in the therapeutic international normalised ratio range. Where reported, most of the patients were hypertensive and at a high risk of stroke (CHADS2 score 3 or above); 31% to 40% of patients were receiving aspirin; 39% to 45% had not received a VKA before entry into the study; and over 60% were male.
The authors did not report the number of reviewers who selected studies for the review.
Assessment of study quality
A systematic assessment of study quality did not seem to have been undertaken.
Data extraction
Two reviewers independently extracted data on the incidence of stroke/systemic embolism, various stroke outcomes, allcause and cardiovascular death, myocardial infarction and bleeding outcomes in order to calculate odds ratios and 95% confidence intervals; absolute risk reduction, relative risk reduction and the number-needed-to-treat were also calculated. Study authors were contacted for missing data. Disagreements between reviewers were resolved by discussion or referral to the review team.
Methods of synthesis
Pooled Peto odds ratios and 95% confidence intervals were calculated; this is a fixed-effect model. Heterogeneity was assessed using Ι².
Results of the review
Three RCTs were included in the review (14,527 patients; range 3,436 to 7,468) . The duration of follow-up ranged from 1.8 to two years. Compared to warfarin, non-VKAs resulted in a statistically significant reduction in the incidence of stroke/systemic embolism (OR 0.85, 95% CI 0.74 to 0.99; Ι² 0%), haemorrhagic stroke (OR 0.44, 95% CI 0.32 to 0.62; Ι² 58%), major bleeding (OR 0.86, 95% CI 0.75 to 0.99; Ι² 52%), and intracranial bleeding (OR 0.47, 95% CI 0.36 to 0.62; 60%). No significant differences were observed between the non-VKAs and warfarin for the incidence of
